Open AccessIntravenous Immunoglobulin to Suppress Progression in a Patient With Advanced Breast Cancer
Author(s) -
Kai-Liang Lin,
TaChung Chao,
MingHan Chen
Publication year - 2022
Publication title -
journal of breast cancer/journal of breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 36
eISSN - 2092-9900
pISSN - 1738-6756
DOI - 10.4048/jbc.2022.25.e8
Subject(s) - medicine , breast cancer , melanoma , chemotherapy , cancer , antibody , metastatic breast cancer , lung cancer , oncology , sarcoma , immune system , immunotherapy , immunology , pathology , cancer research
Intravenous immunoglobulin (IVIG) is used to treat various diseases and has anticancer effects that suppress metastases in animal models of sarcoma and melanoma. However, these effects have been observed in a limited number of clinical cases. We report the case of a patient with metastatic breast cancer in which long-term IVIG treatment stopped disease progression in the absence of salvage chemotherapy. The patient was treated with IVIG for the treatment of immune thrombocytopenia. Surprisingly, the lung and brain metastases were stabilized, and the patient achieved a progression-free interval of 29 months. More cases are needed to investigate and confirm the efficacy of IVIG in solid tumors in the future.